AUPH - (Aurinia Pharmaceuticals Inc)

 AUPHのチャート


 AUPHの企業情報

symbol AUPH
会社名
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種   
概要 事業概要 --     
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/auph
adr_tso
EBITDA EBITDA ー
終値(lastsale) 6.1601
時価総額(marketcap) 525599241.0367
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 AUPHのテクニカル分析


 AUPHのニュース

   Aurinia Pharma Stock Showing A Potential Reversal Pattern: 4 Key Levels To Watch  2021/04/20 22:35:14 Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) was trending Tuesday afternoon possibly amid the stock making a new 52-week low. Below are the technical levels to watch on the chart. Aurinia Daily Chart Analysis: The stock is trading below both the 50-day moving average (green) as well as the 200-day moving average (blue). This indicates the stock has had bearish sentiment before the announcement of coverage Tuesday. The moving averages are areas on the chart that may show … Full story available on Benzinga.com
   H.C. Wainwright Stick to Their Buy Rating for Aurinia Pharmaceuticals By Investing.com  2021/04/08 15:25:02 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Aurinia Pharmaceuticals
   Aurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data Shows  2021/04/08 11:38:21 Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) has presented additional efficacy data from the AURA-LV and AURORA 1 trials of Lupkynis (voclosporin) in lupus nephritis (LN). Aurinia shared the data at the National Kidney Foundation 2021 Spring Clinical Meeting. Pooled data from the AURA-LV and AURORA 1 study demonstrate that Lupkynis, combined with mycophenolate mofetil (MMF) and low-dose corticosteroids, led to treatment … Full story available on Benzinga.com
   Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021  2021/02/17 11:05:00 Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update. The conference call and webcast is scheduled for February 24, 2021 at 4:30pm ET. In order to p
   Insider Buying: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Purchases 1,200 Shares of Stock  2021/02/04 11:58:52 Watchlist News
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) Director Jill Leversage bought 1,200 shares of the company’s stock in a transaction on Friday, January 29th. The stock was purchased at an average price of $16.03 per share, with a total value of $19,236.00. Following the completion of the transaction, the director now directly owns 1,200 shares of the […]
   Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021  2021/02/17 11:05:00 Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update. The conference call and webcast is scheduled for February 24, 2021 at 4:30pm ET. In order to p
   Insider Buying: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Purchases 1,200 Shares of Stock  2021/02/04 11:58:52 Watchlist News
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) Director Jill Leversage bought 1,200 shares of the company’s stock in a transaction on Friday, January 29th. The stock was purchased at an average price of $16.03 per share, with a total value of $19,236.00. Following the completion of the transaction, the director now directly owns 1,200 shares of the […]
   Shark Bites: Anatomy of a Trade - Aurinia Pharmaceuticals  2021/02/01 17:45:15 The Street RealMoney
Anatomy of a Trade - Aurinia Pharmaceuticals (AUPH)…AUPH
   Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates  2021/01/31 10:22:17 Benzinga
Coming off a stellar year, when a record 53 new molecular entities were approved, 2021 has a lot to live up to. NMEs are a measure of innovation among biopharma companies, as they refer to drugs containing an active ingredient that has never been approved previously. Although the calendar for drug approval decisions, known as PDUFA dates, for January was fairly light, most verdicts issued in the month were positive. Among the drugs approved in the month were Merck & Co., Inc. 's (NYSE: MRK ) heart failure drug, an expanded indication for Pfizer Inc. 's (NYSE: PFE ) lymphoma drug and Aurinia Pharmaceuticals Inc 's (NASDAQ: AUPH ) kidney inflammation drug. Here are the key FDA decisions due for February: Adamas Seeks Label Expansion For Its Parkinson's Drug Company: Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Type of Application: sNDA Candidate: Gocovri Indication: "Off episodes" in Parkinson's disease patients receiving levodopa-based therapy Date: Feb. 1 (estimated date provided by the company) The FDA accepted the application for label expansion on June 4.
   Why Aurinia Pharma, AstraZeneca And More Are Trading Higher Today  2021/01/25 11:29:00 Benzinga
AstraZeneca (NASDAQ: AZN) shares are trading higher Monday after the company's CALQUENCE met its primary efficacy endpoint. The German Health Minister …
   Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021  2021/02/17 11:05:00 Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update. The conference call and webcast is scheduled for February 24, 2021 at 4:30pm ET. In order to p
   Insider Buying: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Purchases 1,200 Shares of Stock  2021/02/04 11:58:52 Watchlist News
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) Director Jill Leversage bought 1,200 shares of the company’s stock in a transaction on Friday, January 29th. The stock was purchased at an average price of $16.03 per share, with a total value of $19,236.00. Following the completion of the transaction, the director now directly owns 1,200 shares of the […]
   Shark Bites: Anatomy of a Trade - Aurinia Pharmaceuticals  2021/02/01 17:45:15 The Street RealMoney
Anatomy of a Trade - Aurinia Pharmaceuticals (AUPH)…AUPH
   Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates  2021/01/31 10:22:17 Benzinga
Coming off a stellar year, when a record 53 new molecular entities were approved, 2021 has a lot to live up to. NMEs are a measure of innovation among biopharma companies, as they refer to drugs containing an active ingredient that has never been approved previously. Although the calendar for drug approval decisions, known as PDUFA dates, for January was fairly light, most verdicts issued in the month were positive. Among the drugs approved in the month were Merck & Co., Inc. 's (NYSE: MRK ) heart failure drug, an expanded indication for Pfizer Inc. 's (NYSE: PFE ) lymphoma drug and Aurinia Pharmaceuticals Inc 's (NASDAQ: AUPH ) kidney inflammation drug. Here are the key FDA decisions due for February: Adamas Seeks Label Expansion For Its Parkinson's Drug Company: Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Type of Application: sNDA Candidate: Gocovri Indication: "Off episodes" in Parkinson's disease patients receiving levodopa-based therapy Date: Feb. 1 (estimated date provided by the company) The FDA accepted the application for label expansion on June 4.
   Why Aurinia Pharma, AstraZeneca And More Are Trading Higher Today  2021/01/25 11:29:00 Benzinga
AstraZeneca (NASDAQ: AZN) shares are trading higher Monday after the company's CALQUENCE met its primary efficacy endpoint. The German Health Minister …

 関連キーワード  (― 米国株 AUPH Aurinia Pharmaceuticals Inc)

 twitter  (公式ツイッターやCEOツイッターなど)